BR112022015977A2 - Anticorpos anti-axl e composições - Google Patents
Anticorpos anti-axl e composiçõesInfo
- Publication number
- BR112022015977A2 BR112022015977A2 BR112022015977A BR112022015977A BR112022015977A2 BR 112022015977 A2 BR112022015977 A2 BR 112022015977A2 BR 112022015977 A BR112022015977 A BR 112022015977A BR 112022015977 A BR112022015977 A BR 112022015977A BR 112022015977 A2 BR112022015977 A2 BR 112022015977A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- axl antibodies
- axl
- antibodies
- diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS ANTI-AXL E COMPOSIÇÕES. A presente invenção refere-se a anticorpos anti-AXL e métodos para usá-los no tratamento de doenças e condições relacionadas à atividade de AXL, por exemplo, câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982852P | 2020-02-28 | 2020-02-28 | |
PCT/IB2021/051636 WO2021171257A1 (en) | 2020-02-28 | 2021-02-26 | Anti-axl antibodies and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022015977A2 true BR112022015977A2 (pt) | 2022-10-11 |
Family
ID=75426640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022015977A BR112022015977A2 (pt) | 2020-02-28 | 2021-02-26 | Anticorpos anti-axl e composições |
Country Status (16)
Country | Link |
---|---|
US (1) | US11807688B2 (pt) |
EP (1) | EP4110824A1 (pt) |
JP (1) | JP2023515821A (pt) |
KR (1) | KR20220148237A (pt) |
CN (1) | CN115210263A (pt) |
AR (1) | AR121441A1 (pt) |
AU (1) | AU2021225490A1 (pt) |
BR (1) | BR112022015977A2 (pt) |
CA (1) | CA3170975A1 (pt) |
CL (1) | CL2022002259A1 (pt) |
CO (1) | CO2022012159A2 (pt) |
IL (1) | IL295596A (pt) |
MX (1) | MX2022010670A (pt) |
PE (1) | PE20221783A1 (pt) |
TW (1) | TW202146455A (pt) |
WO (1) | WO2021171257A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US9175091B2 (en) | 2007-11-15 | 2015-11-03 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
EP2582729A4 (en) | 2010-06-18 | 2014-05-28 | Hoffmann La Roche | ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE |
AU2015366213B2 (en) | 2014-12-18 | 2021-10-07 | Bergenbio Asa | Anti-Axl antagonistic antibodies |
JP6892431B2 (ja) | 2015-07-10 | 2021-06-23 | ゲンマブ エー/エス | 癌治療用のaxl特異的抗体−薬物コンジュゲート |
GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
AU2019250443A1 (en) * | 2018-04-10 | 2020-10-22 | Genmab A/S | AXL-specific antibodies for cancer treatment |
-
2021
- 2021-02-26 AR ARP210100499A patent/AR121441A1/es unknown
- 2021-02-26 PE PE2022001857A patent/PE20221783A1/es unknown
- 2021-02-26 AU AU2021225490A patent/AU2021225490A1/en active Pending
- 2021-02-26 IL IL295596A patent/IL295596A/en unknown
- 2021-02-26 WO PCT/IB2021/051636 patent/WO2021171257A1/en active Application Filing
- 2021-02-26 CN CN202180017213.3A patent/CN115210263A/zh active Pending
- 2021-02-26 MX MX2022010670A patent/MX2022010670A/es unknown
- 2021-02-26 CA CA3170975A patent/CA3170975A1/en active Pending
- 2021-02-26 JP JP2022551247A patent/JP2023515821A/ja active Pending
- 2021-02-26 KR KR1020227033462A patent/KR20220148237A/ko unknown
- 2021-02-26 EP EP21717200.6A patent/EP4110824A1/en active Pending
- 2021-02-26 US US17/186,465 patent/US11807688B2/en active Active
- 2021-02-26 BR BR112022015977A patent/BR112022015977A2/pt unknown
- 2021-03-02 TW TW110107402A patent/TW202146455A/zh unknown
-
2022
- 2022-08-18 CL CL2022002259A patent/CL2022002259A1/es unknown
- 2022-08-25 CO CONC2022/0012159A patent/CO2022012159A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022012159A2 (es) | 2022-10-31 |
IL295596A (en) | 2022-10-01 |
KR20220148237A (ko) | 2022-11-04 |
PE20221783A1 (es) | 2022-11-16 |
TW202146455A (zh) | 2021-12-16 |
CA3170975A1 (en) | 2021-09-02 |
US11807688B2 (en) | 2023-11-07 |
JP2023515821A (ja) | 2023-04-14 |
CL2022002259A1 (es) | 2023-04-14 |
MX2022010670A (es) | 2022-09-23 |
EP4110824A1 (en) | 2023-01-04 |
AU2021225490A1 (en) | 2022-09-15 |
CN115210263A (zh) | 2022-10-18 |
AR121441A1 (es) | 2022-06-08 |
WO2021171257A1 (en) | 2021-09-02 |
US20210269532A1 (en) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
BR112019006876A2 (pt) | anticorpos e composições anti-lag-3 | |
BR112018006257A2 (pt) | anticorpos anti-pd-1 e composições | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
BR112018072986A2 (pt) | anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
MX2019010848A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
MX2022009596A (es) | Anticuerpos anti-ror1 y composiciones. | |
BR112021024236A2 (pt) | Proteínas multiespecíficas | |
BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
MX2020012107A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
AR114129A1 (es) | ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS | |
CL2022000294A1 (es) | Composiciones biofarmacéuticas y procedimientos conexos. | |
BR112022001199A2 (pt) | Imunoterapia para poliomavírus | |
BR112022015977A2 (pt) | Anticorpos anti-axl e composições | |
ECSP22004680A (es) | Anticuerpos anti-angpt2 | |
BR112022024988A2 (pt) | Compostos e métodos para tratamento de infecções fúngicas | |
CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: LES LABORATOIRES SERVIER (FR) |